根据协议条款，博奥信将获得超过4000万美元的现金付款，作为首付款以及承担部分开发成本和药物产品材料费用。博奥信还将获得Aclaris Therapeutics ...

▲点击上方的蓝色“医谷”关注我们日前，博奥信生物宣布与Aclaris ...

周二，Aclaris Therapeutics (NASDAQ: ACRS)宣布与Biosion达成重要的许可协议，获得两种潜在炎症治疗药物的全球权利（不包括中国）。这些许可的化合物包括BSI-045B（也称为TQC2731，一种抗TSLP单克隆抗体）和BSI-502（一种抗TSLP加抗IL4R双特异性抗体），两者都旨在治疗特应性皮炎和其他炎症性疾病。 公告详细介绍了Aclaris分享的BSI-0 ...

- 博奥信将获得超过4000万美元的现金付款，作为首付款以及承担部分开发成本和药物产品材料费用，同时博奥信还将获得 Aclaris Therapeutics 19.9% ...

BSI-045B is also being advanced in multiple Phase 2 studies in China by Biosion’s regional partner, Chia Tai Tianqing ...

Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets: Newark, Delaware Wednesday, November 20, ...

Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first anti-TSLP showing clinical proof of concept in atopic dermatitis, which is ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Don't Miss our Black Friday Offers: Roger Song’s rating is based on the promising potential of Aclaris Therapeutics’ BSI-045B, an anti-TSLP antibody that has demonstrated clinical proof of concept in ...

Biosion, Inc., a R&D stage biotechnology company, announced Monday that it has entered into an exclusive license agreement with ...

周二，BTIG将Aclaris Therapeutics Inc. (NASDAQ:ACRS)的股票评级从中性上调至买入。该公司还为Aclaris设定了8.00美元的新目标价，表明对该公司股票前景持积极态度。